FDA OKs Tandem's t:slim X2 insulin pump with hypoglycemia management feature; shares up 1% after hours

|By:, SA News Editor

Tandem Diabetes Care (NASDAQ:TNDM) is up 1% after hours on light volume on the heels of the FDA's approval of its t:slim X2 Insulin Pump with Basal-IQ, a predictive low glucose suspend feature aimed at reducing the frequency and duration of hypoglycemic (low blood sugar) events.

The device is approved for use by diabetics as young as six years.

Related tickers: SENS, DXCM, ABT, MDT, PODD

Subscribe for full text news in your inbox